N
STOK icon

Nuveen’s Stoke Therapeutics STOK Stock Holding History

Nuveen’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.54M Buy
108,617
+4,356
+4% +$143K ﹤0.01% 2039
2025
Q4 		$3.31M Sell
104,261
-1,733
-2% -$52.1K ﹤0.01% 2090
2025
Q3 		$2.49M Buy
105,994
+3,526
+3% +$60.4K ﹤0.01% 2212
2025
Q2 		$1.16M Sell
102,468
-5,619
-5% -$53.4K ﹤0.01% 2534
2025
Q1 		$719K Hold
108,087
– – ﹤0.01% 2774
2024
Q4 		$1.19M Hold
108,087
– – ﹤0.01% 2636
2024
Q3 		$1.33M Sell
108,087
-79,264
-42% -$1.12M ﹤0.01% 2631
2024
Q2 		$2.53M Buy
187,351
+67,540
+56% +$912K ﹤0.01% 2270
2024
Q1 		$1.62M Buy
119,811
+56,480
+89% +$342K ﹤0.01% 2491
2023
Q4 		$333K Buy
63,331
+467
+0.7% +$2K ﹤0.01% 3126
2023
Q3 		$248K Sell
62,864
-763
-1% -$5.02K ﹤0.01% 2997
2023
Q2 		$676K Buy
63,627
+7,568
+14% +$80.5K ﹤0.01% 2830
2023
Q1 		$467K Sell
56,059
-6,525
-10% -$58.9K ﹤0.01% 2821
2022
Q4 		$578K Sell
62,584
-37,781
-38% -$393K ﹤0.01% 2848
2022
Q3 		$1.29M Buy
100,365
+26,329
+36% +$420K ﹤0.01% 2629
2022
Q2 		$978K Buy
74,036
+16,157
+28% +$245K ﹤0.01% 2788
2022
Q1 		$1.39M Buy
57,879
+722
+1% +$14.5K ﹤0.01% 2676
2021
Q4 		$1.02M Sell
57,157
-4,672
-8% -$111K ﹤0.01% 2856
2021
Q3 		$1.56M Sell
61,829
-30,621
-33% -$854K ﹤0.01% 2790
2021
Q2 		$3.11M Buy
92,450
+40,860
+79% +$1.44M ﹤0.01% 2493
2021
Q1 		$2M Buy
51,590
+480
+0.9% +$27.3K ﹤0.01% 2621
2020
Q4 		$3.17M Buy
51,110
+1,145
+2% +$52.5K ﹤0.01% 2284
2020
Q3 		$1.67M Sell
49,965
-6,183
-11% -$177K ﹤0.01% 2469
2020
Q2 		$1.34M Sell
56,148
-29,962
-35% -$711K ﹤0.01% 2497
2020
Q1 		$1.97M Buy
86,110
+64,698
+302% +$1.6M ﹤0.01% 2198
2019
Q4 		$606K Sell
21,412
-1,987
-8% -$50K ﹤0.01% 2860
2019
Q3 		$503K Buy
+23,399
New +$653K ﹤0.01% 2945

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Nuveen's STOK Position: Q1 2026 in Review

Nuveen increased its Stoke Therapeutics (STOK) stake by 4.2% in Q1 2026, buying an estimated $143K and bringing the position to 108,617 shares worth $3.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2039.

Nuveen first reported a position in STOK in Q3 2019 and has held it in 27 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Nuveen held 108,617 shares of Stoke Therapeutics worth $3.54M as of Q1 2026.
  • Nuveen bought 4,356 Stoke Therapeutics shares in Q1 2026, an estimated $143K.
  • Stoke Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2039 holding.
  • Nuveen first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.